ABSTRACT
In this study, acrylic-epoxy-based nanocomposite coatings loaded with different concentrations (0.5-3 wt.%) of graphene oxide (GO) nanoparticles were successfully prepared via the solution intercalation approach. The thermogravimetric analysis (TGA) revealed that the inclusion of GO nanoparticles into the polymer matrix increased the thermal stability of the coatings. The degree of transparency evaluated by the ultraviolet-visible (UV-Vis) spectroscopy showed that the lowest loading rate of GO (0.5 wt.%) had completely blocked the incoming irradiation, thus resulting in zero percent transmittance. Furthermore, the water contact angle (WCA) measurements revealed that the incorporation of GO nanoparticles and PDMS into the polymer matrix had remarkably enhanced the surface hydrophobicity, exhibiting the highest WCA of 87.55º. In addition, the cross-hatch test (CHT) showed that all the hybrid coatings exhibited excellent surface adhesion behaviour, receiving 4B and 5B ratings respectively. Moreover, the field emission scanning electron microscopy (FESEM) micrographs confirmed that the presence of the functional groups on the GO surface facilitated the chemical functionalization process, which led to excellent dispersibility. The GO composition up to 2 wt.% showed excellent dispersion and uniform distribution of the GO nanoparticles within the polymer matrix. Therefore, the unique features of graphene and its derivatives have emerged as a new class of nanofillers/inhibitors for corrosion protection applications.
ABSTRACT
Globally, researchers have devoted consistent efforts to producing excellent coating properties since coating plays an essential role in enhancing electrochemical performance and surface quality. In this study, TiO2 nanoparticles in varying concentrations of 0.5, 1, 2, and 3 wt.% were added into the acrylic-epoxy polymeric matrix with 90:10 wt.% (90A:10E) ratio incorporated with 1 wt.% graphene, to fabricate graphene/TiO2 -based nanocomposite coating systems. Furthermore, the properties of the graphene/TiO2 composites were investigated by Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), ultraviolet-visible (UV-Vis) spectroscopy, water contact angle (WCA) measurements, and cross-hatch test (CHT), respectively. Moreover, the field emission scanning electron microscope (FESEM) and the electrochemical impedance spectroscopy (EIS) tests were conducted to investigate the dispersibility and anticorrosion mechanism of the coatings. The EIS was observed by determining the breakpoint frequencies over a period of 90 days. The results revealed that the TiO2 nanoparticles were successfully decorated on the graphene surface by chemical bonds, which resulted in the graphene/TiO2 nanocomposite coatings exhibiting better dispersibility within the polymeric matrix. The WCA of the graphene/TiO2 coating increased along with the ratio of TiO2 to graphene, achieving the highest CA of 120.85° for 3 wt.% of TiO2. Excellent dispersion and uniform distribution of the TiO2 nanoparticles within the polymer matrix were shown up to 2 wt.% of TiO2 inclusion. Among the coating systems, throughout the immersion time, the graphene/TiO2 (1:1) coating system exhibited the best dispersibility and high impedance modulus values (Z0.01 Hz), exceeding 1010 Ω cm2.
ABSTRACT
IntroductionA single center open label phase II randomised control trial was done to assess the pathogen and host-intrinsic factors influencing clinical and immunological benefits of passive immunization using convalescent plasma therapy (CPT), in addition to standard of care (SOC) therapy in severe COVID-19 patients, as compared to patients only on SOC therapy. MethodsConvalescent plasma was collected from patients recovered from COVID-19 following a screening protocol which also included measuring plasma anti SARS-CoV2 spike IgG content. Retrospectively, neutralizing antibody content was measured and proteome was characterized by LC-MS/MS for all convalescent plasma units that were transfused to patients. Severe COVID-19 patients with evidence for acute respiratory distress syndrome (ARDS) with PaO2/FiO2 ratio 100-300 (moderate ARDS) were recruited and randomised into two parallel arms of SOC and CPT, N=40 in each arm. Peripheral blood samples were collected on the day of enrolment (T1) followed by day3/4 (T2) and day 7 (T3). RT-PCR and sequencing was done for SARS-CoV2 RNA isolated from nasopharyngeal swabs collected at T1. A panel of cytokines and neutralizing antibody content were measured in plasma at all three timepoints. Patients were followed up for 30 days post-admission to assess the primary outcomes of all cause mortality and immunological correlates for clinical benefits. ResultsWhile across all age-groups no statistically significant clinical benefit was registered for patients in the CPT arm, significant immediate mitigation of hypoxia, reduction in hospital stay as well as survival benefit was recorded in severe COVID-19 patients with ARDS aged less than 67 years receiving convalescent plasma therapy. In addition to its neutralizing antibody content a prominent effect of convalescent plasma on attenuation of systemic cytokine levels possibly contributed to its benefits. ConclusionPrecise targeting of severe COVID-19 patients is necessary for reaping the clinical benefits of convalescent plasma therapy. Clinical trial registrationClinical Trial Registry of India No. CTRI/2020/05/025209
ABSTRACT
In a randomized control trial on convalescent plasma therapy (CPT) in severe COVID-19, we characterized the nature, in terms of abundance of forty eight cytokines, and dimensions, in terms of their interrelationships, of the hyper-immune activation-associated cytokine storm in patients suffering from acute respiratory distress syndrome. We found reduced plasma level of the chemokine MCP3 to be a key correlate for clinical improvement, irrespective of therapeutic regimen. We also identified an anti-inflammatory role of CPT independent of its neutralizing antibody content, and a linear regression analysis revealed that neutralizing antibodies as well as the anti-inflammatory effect of CPT both contribute to marked immediate reductions in hypoxia, as compared to patients on standard therapy.
